• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

OLYSIO - Articles and news items

Janssen Pharmaceuticals Logo

OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

Industry news, News / 19 May 2014 / Janssen Pharmaceutical Companies

Janssen-Cilag International NV today announced that its next generation protease inhibitor OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission for the treatment of adults with genotype 1 and 4 chronic hepatitis C…

Janssen Pharmaceuticals Logo

OLYSIO™ (simeprevir) receives FDA approval for combination treatment of chronic hepatitis C

Industry news / 22 November 2013 / Johnson & Johnson

OLYSIO™ works by blocking the viral protease enzyme that enables the hepatitis C virus (HCV) to replicate in host cells…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +